ERBB2 and breast carcinoma: Using the methods outlined above, we identified a total of 338 patients during the 4-year period 1 January 2005 to 31 December, 20 as having undergone surgery for stage I–III HER2+ breast cancer and referred for consideration of adjuvant therapy with Trastuzumab (Figure 1).